Communiqués Avacta Group Plc

Actions

AVCT

GB00BYYW9G87

Recherche biotechnologique et médicale

Marché Fermé - London S.E. 17:35:18 06/10/2026			Varia. 5j.	Varia. 1 janv.
68,00 ^GBX	-5,56%		-5,56%	+17,24%

09:05	Avacta Group lève 12,5 millions de livres sterling grâce à une cession d’actions	MT
06:55	Avacta Group cherche à lever 13 millions de livres sterling via une émission d’actions	MT

Communiqués

11:06	Avacta : RESTORATION OF TRADING ON AIM	PU
11:06	Avacta : Results of Placing and Subscription	PU
30/09	Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update	GL
30/09	Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update	AQ
25/09	Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer	GL
16/09	Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre\|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial	GL
16/09	Avacta : Research & Development Spotlight Series – Episode 16	PU
16/09	Avacta : Achieves Clinical Proof of Mechanism for the Next Generation of pre\|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial	PU
14/09	Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee	GL
23/07	Avacta : Research & Development Spotlight Series – Episode 15	PU
21/07	Avacta : Academy – Episode 4	PU
09/07	Avacta : Accelerated Amortized Payment of Convertible Bond Installment	PU
08/07	Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors	GL
25/06	Avacta : Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer	PU
01/06	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	GL
01/06	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	AQ
29/05	Avacta : Annual Report and Accounts for the year ending 31 December 2025	PU
19/05	Unaudited Preliminary Results for the Year Ended December 31, 2025	GL
06/05	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	PU
06/05	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	GL
21/04	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform	GL
14/04	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders	GL
08/04	Avacta : Announces 2026 Science Day Event	PU
31/03	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate	GL
27/03	Avacta : Results of Oversubscribed Placing and Subscription	PU